Second line systemic therapy options for advanced hepatocellular carcinoma; a systematic review

Area of Science:

• Hepatology
• Medical Oncology
• Clinical Evidence Synthesis

Background:

• Hepatocellular carcinoma (HCC) is a significant global health concern.
• Optimal second-line systemic therapy remains an area of active research.
• Evaluating existing evidence is crucial for guiding clinical practice.

Purpose of the Study:

• To systematically review and evaluate the level of evidence for second-line systemic therapies in HCC.
• To synthesize efficacy and toxicity data from eligible studies.
• To identify areas requiring further investigation.

Main Methods:

• Systematic literature search of relevant databases.
• Inclusion of studies reporting efficacy and/or toxicity data for second-line systemic chemotherapy in HCC.
• Analysis of data from 25 eligible studies.

Main Results:

• Median progression-free survival ranged from 1.8 to 11 months (reported in 20 studies).
• Median overall survival ranged from 6.6 to 16 months (reported in 18 studies).
• Grade 3/4 toxicities included hepatotoxicity, hypertension, and hematologic toxicities, varying by regimen.

Conclusions:

• Current evidence for second-line systemic therapy in HCC shows a range of outcomes.
• Positive findings for some agents require validation through prospective clinical trials.
• Further research is essential to establish definitive treatment guidelines.